Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacia delle cellule stromali mesenchimali allogeniche consegnate localmente

1 novembre 2026 aggiornato da: Ali R Djalilian, University of Illinois Chicago

Efficacia delle cellule staminali mesenchimali allogeniche consegnate localmente per promuovere la riparazione corneale

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

The "Efficacy of Locally Delivered Allogeneic Mesenchymal Stem Cells for Promoting Corneal Repair Study" otherwise known as the "MSC Study," is designed to assess the safety of allogeneic bone marrow-derived MSC secreted factor on the ocular surface via subconjunctival injection of MSC, and also obtain a preliminary observation on the following:

  • Epithelial barrier integrity and/or wound closure.
  • Development of Scarring.
  • Final Visual Acuity.

The objective is to improve clinical outcomes in significant non-healing corneal wounds. To achieve these goals, the MSC Study will include a Phase II efficacy study.

Tipo di studio

Interventistico

Iscrizione (Stimato)

38

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Ali R Djalilian, MD
  • Numero di telefono: 312-996-8937
  • Email: adjalili@uic.edu

Backup dei contatti dello studio

  • Nome: Charlotte E Joslin, OD, PhD
  • Numero di telefono: 312-996-5410
  • Email: charjosl@uic.edu

Luoghi di studio

    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Reclutamento
        • Department of Ophthalmology and Visual Sciences
        • Contatto:
        • Contatto:
          • Charlotte E Joslin, OD, PhD
          • Numero di telefono: 312-996-5410
          • Email: charjosl@uic.edu
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21201
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Attivo, non reclutante
        • Mass Eye and Ear Infirmary
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Attivo, non reclutante
        • University of Pennsylvania, Scheie Eye Institute

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Ocular Health:

  • Patients with non-resolving corneal epitheliopathy or epithelial defect after two or more weeks of standard non-surgical treatments (e.g., preservative-free artificial tears, gels or ointments; discontinuation of preserved topical drops; anti-inflammatory therapy, soft bandage contact lens).
  • No objective clinical evidence of improvement in the last 2 weeks (≤50% reduction in fluorescein staining or ≤50% reduction in longest diameter of the epithelial defect).
  • If both eyes have chronic epithelial disease, the eye with the worse epithelial disease will be treated.
  • Evidence of impaired epithelial barrier manifested by fluorescein staining of the epithelium with a score 6 or higher by National Eye Institute grading.
  • Patients with stage 1 (no epithelial defect), stage 2 (persistent epithelial defect, PED; without stromal loss) or stage 3 (corneal ulcer; with stromal loss) neurotrophic keratopathy25-27 limited to ≤80% corneal diameter.

Study Procedures:

  • Only patients who satisfy all Informed Consent requirements may be included in the study. The patient and/or his/her legal representative must read, sign and date the Informed Consent document before any study-related procedures are performed. The Informed Consent form signed by patients and/or legal representatives must have been approved by the IRB for the current study.
  • Patients must have the ability and willingness to comply with study procedures.

Exclusion Criteria:

Visual Acuity:

Ocular Health:

  • Ocular drug toxicity less than two weeks ago
  • Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation in the affected eye.
  • History of any ocular surgery (including laser or refractive surgical procedures) in the affected eye within the three months before study enrollment. (An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the PED. Ocular surgery in the affected eye will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period unless the patient will be involved in corneal thinning of more than 1/3 corneal stroma, corneal melting or perforation.
  • Prior surgical procedure(s) for the treatment of a chronic corneal epitheliopathy (e.g., complete tarsorrhaphy, conjunctival flap, etc.) in the affected eye with the exception of amniotic membrane transplantation. Patients previously treated with amniotic membrane transplantation may only be enrolled two weeks after the membrane has disappeared within the area of the chronic corneal epitheliopathy or corneal ulcer or at least six weeks after the date of the amniotic membrane transplantation procedure. Patients previously treated with Botox (botulinum toxin) injections used to induce pharmacologic blepharoptosis are eligible for enrollment only if the last injection was given at least 90 days prior to enrollment in the study.
  • Chronic corneal epitheliopathy in the background of endothelial decompensation that needs corneal graft
  • Anticipated need for punctual occlusion during the study treatment period. Patients with punctual occlusion or punctual plugs inserted prior to the study are eligible for enrollment provided that the punctual occlusion is maintained during the study.
  • Evidence of corneal ulceration involving the posterior third of the corneal stroma, corneal melting or perforation in the affected eye.
  • Presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (e.g., progressive or degenerative corneal or retinal conditions, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases).
  • Patients with uncontrolled eyelid abnormality that preclude appropriate eyelid closure or including eyelash abnormality

Study Procedures:

  • Known hypersensitivity to one of the components of the study or procedural medications (e.g., fluorescein).
  • History of drug, medication or alcohol abuse or addiction.
  • Use of any investigational agent within 4 weeks of screening visit.
  • Participation in another clinical study at the same time as the present study.
  • Participants who are pregnant at the time of study enrollment will be excluded; pregnancy is identified according to the patient's self-report /positive βhCG

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Medium dose of allogenic MSC drops

Dose of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL.

Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.

Comparatore fittizio: Control Group

For the control group, 50 µL of the freezing media (vehicle) will be injected.

For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Improvement of Corneal Epithelial Barrier and/or Integrity (Efficacy Rate)
Lasso di tempo: Day 28

The proportion of patients with improved epithelial barrier and/or integrity from baseline to DAY 28 as determined by the investigator on slit lamp examination:

  • Improved epithelial barrier, defined as a 50 % improvement in corneal fluorescein staining score
  • Improved epithelial integrity, defined as a healed epithelial defect
Day 28

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Visual Acuity
Lasso di tempo: Baseline, Days 1-7, 28, 60, 90

Percent change in best-corrected distance visual acuity from baseline to DAY 90, as measured using standard ETDRS protocols

Baseline, Days 1-7, 28, 60, 90
Corneal staining and NEI grading
Lasso di tempo: Baseline, Days 1-7, 28, 60, 90

Grading of fluorescein staining of the cornea

Baseline, Days 1-7, 28, 60, 90
Ocular Surface Parameters
Lasso di tempo: Baseline, Day 28, 90

Changes in tear breakup time (TBUT), ocular surface disease index (OSDI), Lissamine green staining, and anesthetic Schirmer's test from baseline to DAY 28 and DAY 90

Baseline, Day 28, 90
Corneal Epithelial Thickness
Lasso di tempo: Day 28, 90

Percent change in corneal epithelial thickness from baseline to DAY 28 and DAY 90, as measured by anterior segment OCT (AS-OCT)

Day 28, 90
Patient Symptoms
Lasso di tempo: Baseline, Days 1-7, 28, 60, 90

Changes in ocular discomfort visual analog scale (VAS) 0 - 100, where 0 is no discomfort and 100 the worst discomfort, from baseline to DAY 90

Baseline, Days 1-7, 28, 60, 90
Time to epithelial healing
Lasso di tempo: Baseline, Days 1-7, 28, 60, 90

Time of improvement of epitheliopathy

Baseline, Days 1-7, 28, 60, 90
Corneal Scar
Lasso di tempo: Baseline, Days 1-7, 28, 60, 90

Change in the size of corneal scar (if present) from baseline to DAY 90, as documented by slit lamp photographs

Baseline, Days 1-7, 28, 60, 90
Corneal Neo-vascularization
Lasso di tempo: Baseline, Days 1-7, 28, 60, 90

Change in corneal vascularization on slit lamp photographs from baseline to DAY 90

Baseline, Days 1-7, 28, 60, 90
Conjunctival injection
Lasso di tempo: Baseline, Days 1-7, 28, 60, 90

Change in conjunctival injection on slit lamp examination from baseline to DAY 90

Baseline, Days 1-7, 28, 60, 90

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Ali R Djalilian, MD, University of Illinois Chicago
  • Investigatore principale: Charlotte E Joslin, OD, PhD, University of Illinois Chicago

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

29 settembre 2023

Completamento primario (Stimato)

28 dicembre 2026

Completamento dello studio (Stimato)

28 dicembre 2026

Date di iscrizione allo studio

Primo inviato

21 gennaio 2023

Primo inviato che soddisfa i criteri di controllo qualità

21 gennaio 2023

Primo Inserito (Effettivo)

30 gennaio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 novembre 2026

Ultimo verificato

1 dicembre 2025

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2022-0751
  • W81XWH-18-1-0661 (Altro numero di sovvenzione/finanziamento: United States Department of Defense)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi